As of July 2026, BPC-157 sits in a regulatory position that has shifted three times in three years. The current state, the 23 to 24 July 2026 PCAC meeting, and what it means for a person trying to source BPC-157 through a legitimate channel.

The 2023 placement

In September 2023, the FDA added BPC-157 to its Category 2 list under the Interim Policy on Compounding Using Bulk Drug Substances. Category 2 means the FDA has evaluated BPC-157 and determined it cannot be used by compounding pharmacies for compounded drugs under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

The agency's reasoning: no adequate evidence of safety or effectiveness in humans, no accepted clinical use, and no pharmacopeial monograph. The placement did not make BPC-157 illegal for an individual to possess. It closed the most medically supervised and legally protected access route that existed at scale.

The 2024 litigation

In September 2024, following litigation by compounding companies (Evexias and Farmakeio) under the Administrative Procedure Act, the FDA agreed to route several restricted peptides through formal advisory committee review. The litigation did not challenge the science, it challenged the process.

The April 2026 shift

On 23 April 2026, the FDA removed BPC-157 from the Category 2 list, following an announcement from HHS. The removal did not constitute approval. It removed one specific barrier while the peptide moves to formal advisory review. As of the date of this article, the FDA's Pharmacy Compounding Advisory Committee is scheduled to meet on 23 and 24 July 2026 to reconsider BPC-157 and six other peptides for inclusion on the 503A Bulks List.

What is and is not legal today

As of the date of this article, the situation is this. Possessing BPC-157 for personal use is not a federal crime. The restriction is on licensed compounding pharmacies manufacturing it at scale. Research chemical vendors operate in a separate legal space: legal to sell for research, not legal to market for human use.

The FDA's 503A compounding pathway remains effectively closed while the PCAC review is pending. Some specialised compounding pharmacies still fill prescriptions under individual exception processes. Physicians retain prescribing discretion in principle, but most 503A pharmacies will not fill the prescription without clear Category 1 status.

What to do in the meantime

If you are a patient: work with a prescriber who understands the regulatory landscape, who can source from a legitimate 503A pharmacy where the law allows, and who can supervise bloodwork and clinical monitoring. The field reference and the older-adult FAQ have the dosing and the safety guardrails.

If you are a prescriber: track the PCAC outcome. If the committee recommends inclusion, the FDA typically follows within 60 to 90 days. If it does not, the Category 2 placement stays and the access model reverts to the pre-2026 grey market.

If you are sourcing research-grade BPC-157 for personal use: third-party testing (HPLC and mass spectrometry) is the practitioner minimum. Ask for a certificate of analysis before reconstituting. Verify the lot number and the date.

What this article is not

This article is not a recommendation to use BPC-157. It is a regulatory summary, current to the date of publication. The peptide landscape moves on a 30-to-90 day cycle. The last-reviewed date on this article is at the top of the page.